All News

Dr. Fiorentino on cancer risk stratification and screening in myositis. Come chat at noon in the Myositis Community Hub to learn more! #ACR21 #ACRAmbassador https://t.co/I0iQuPAuOl
Veena Katikineni VeenaRheumMD ( View Tweet)
Thanks Dr David Fiorentino for his talk on CA and myositis! ⬆️risk: - DM - >45-50yo - males - TIF1-gamma Ab (4.7RR of CA) - NXP2 - low CK - dysphagia ⬇️ risk: - synthetase Ab - raynaud - ILD - inflamm arth 🚨TIF1-gamma🚨 - ovarian CA (older, IgG2) #ACR21 #ACRAmbassador

Vaneet K Sandhu, MD (she/her/hers) vksandhumd ( View Tweet)

Risk Stratification for CA in IIM Low risk: - no clin RF + at least 1 protective factor - autoAb (Jo1, Mi2, MDA5,SRP,RNP/SSA/SSB) Intmdt risk: - 1-2 clin RF - auto Ab (SAE1, HMGCR) - PM/INMN no Ab Hi riks: - >2 clin RF - h/o CA - autoAb (TIF1g, NXP2) #ACR21 #ACRAmbassador https://t.co/nTBSDcS1v4
Vaneet K Sandhu, MD (she/her/hers) vksandhumd ( View Tweet)
Screening for CA in IIM: Low risk: * CXR, age approp CA screen Intmdt risk: * CT c/a/p, tm mrkrs (CA125♀️, PSA♂️), pelvic US, colo <50yo, mammo <50>75) Hi risk (?annually): * whole body PET-CT When? Annual x hi risk? Recalcitrant /Unexpl flare #ACR21 #ACRAmbassador

Vaneet K Sandhu, MD (she/her/hers) vksandhumd ( View Tweet)

#ACR21 #pedsrheum I say it counts! I mean, at the end of the day, these are all just pictures of food on the internet, right? #ACRBakeAnythingChallenge https://t.co/bVQuealWWX

Links:

Dr. Laura Lewandowski LauraLewMad11 ( View Tweet)

Dr. Melissa Munroe - Lupus Classification Risk Immune Index 🔹Pre-/post-classification serum 🔹Avg time➡️classification 4.7y 🔹9 immune mediators altered in pre-clinical dz 🔹Pos score = ⬆️likelihood➡️SLE; Neg = ⬇️ https://t.co/UFEkGieXum 1/2 #ACR21 Abst#1423 @RheumNow #ACRBest

Links:

Pedro Castillo _Castillo_Pedro ( View Tweet)

Late breaking, but just in time! mRNA COVID-19 3rd dose in RTX pts, w/o Ab response post initial series. After 3rd dose many had ab response or T cell response. Extra vaccine full doses can protect RTX pts from COVID! AbsL17 #ACRbest #ACR21 @RheumNow https://t.co/lIDPzybmT7 https://t.co/jEJ3N6cdjK

Links:

Dr. Rachel Tate uptoTate ( View Tweet)
Important late breaker @TerrierBen, DBRCT of RTX vs GC (FFS=0) or CYC (FFS>0) for EGPA RTX not superior to CYC (64% RTX vs 60% CYC BVAS remission d180, p = 0.745); similar in subgroups Feel like this lends support to (~surprising) ACR/VF recs for EGPA? #ACR21 #ACRAmbassador https://t.co/gpsPtXF6pj
Mike Putman EBRheum ( View Tweet)
#ACR21 L19: TitAIN: Secukinumab for GCA ⭐️Phase 2 study with n=52 ⭐️70% of SEC sustained remission at wk 28 vs 20% PBO, 59% at week 52 vs 8% ⬇️Cumulative prednisolone through wk 52 (2.8g v 3.4g) - Looking forward to larger study @Rheumnow https://t.co/cuM9LcEr4u https://t.co/TmyS0kixFg

Links:

Eric Dein ericdeinmd ( View Tweet)
IL-17i for GCA? TitAIN study met all endpoints! phase II: 52 pt DBRPCT 1:1 for 52 weeks secukinumab vs PCB 👉effective sustained remission 👉longer time to GCA flare 👉lower dose of steroids by week 52 👉no increase in AEs #ACR21 @rheumnow Abst#L19 https://t.co/Xi3Iz6Em0R
TheDaoIndex KDAO2011 ( View Tweet)
Increased age at PSO diagnosis was significantly associated with shorter transition time between PSO and PsA diagnoses. No other variables, including BSA, were associated with time to transition @RheumNow #ACR21 Abst#1798 https://t.co/fLPBHKAMAc
Dr. Antoni Chan synovialjoints ( View Tweet)
Composite MACE outcomes no different among PsA pts treated w/ biologics and DMARDs. Abs 1833 #ACR21 #RheumNow #ACRbest @RheumNow https://t.co/TxyE4Uqttq https://t.co/Eykxwmcc44

Links:

Dr. Rachel Tate uptoTate ( View Tweet)
Secukinumab in GCA, phase 2 (TitAIN): I can't deny this is promising, but phase 2 needs to be interesting both arms did worse than equivalents in GiACTA, TCZ phase 2 (?looser flare def) @drpnash: "Bring on the phase 3 trials" (recruitment started👀) #ACR21 ABSTL19 @RheumNow https://t.co/25OAL9BqIZ
David Liew drdavidliew ( View Tweet)
#ACR21 L20- Anti-IFN Ab Emapalumab for MAS/sJIA ⭐️⬆️IFN in models of HLH/MAS, neutralization may be helpful ⭐️Pilot study in 14 pts w inadequate response to high-dose IV GC ⭐️Ok to continue IL1i ▶️13/14 pts remission ▶️ SAEs: 1 CMV reactivation https://t.co/cuM9LcEr4u @RheumNow https://t.co/USYGNtq4eC

Links:

Eric Dein ericdeinmd ( View Tweet)
I am still obsessed with the name MAGIC syndrome -mouth and genital ulcers with inflamed cartilage!! 14% of patients with relapsing polychondritis have this! They also have features of aortitis, Raynaud's phenomenon and anticollagen II antibodies @rheumnow #ACR21 abt#1876 https://t.co/UlQUZlBPfx
Bella Mehta bella_mehta ( View Tweet)
Having an auto-inflammatory disease specialist available via telemedicine/video for near home providers for pts. Well received by primary care, pediatricians and internal medicine physicians. Will improve the care of auto inflammatory patients! #ACR21 @rheumnow #abt1062

Bella Mehta bella_mehta ( View Tweet)

#ACR21 #AbstrL20 A promising new player on the block. A single-arm study of 14 pts with sJIA-associated MAS, Emapalumab (anti-IFNγ) induced remission in all pts with median 25 days, neutralised CXCL9 and allowed rapid steroid reduction @RheumNow #ACRBest https://t.co/7tnaS5tPJ0 https://t.co/G1IoFxLQoX

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
What if a celebrity had #Scleroderma? Would that ⬆️attention & funding for this rare disease? See what Big Bird says @RheumNow #ACR21 ?affected #PetsofACR @RheumNow @scleroderma @SclerodermaCAN audio-13.m4a

Janet Pope Janetbirdope ( View Tweet)

#ACR21 L21. REOVAS: RTX for EGPA ⭐️CYC traditionally preferred for 5-factor score>0 ▶️Remission rates and relapse-free survival comparable bw RTX and conventional. RTX not superior for induction ▶️No diff in ANCA+/-, naive v relapse, FFS https://t.co/cuM9LcEr4u @Rheumnow

Links:

Eric Dein ericdeinmd ( View Tweet)

#Rituximab NOT different from conventional Rx in #eGPA #churgstrauss abst#L21 v small study, 60% ANCA neg #ACR21 @RheumNow https://t.co/tO1vAF18y9
Janet Pope Janetbirdope ( View Tweet)
×